Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS JANUARY ISSUE PUBLISHED
  • JANUARY 2021 Issue has been successfully launched on 1 January 2021.

Abstract

BIO-EQUIVALENCE STUDY OF TWO ORAL SPIRAMYCIN FORMULATIONS (SUANOVIL 50® AND SPIRAVETOX®) IN BROILER CHICKENS

Ashraf Elkomy* and Mohamed Aboubakr

ABSTRACT

The present study was designed to assess the comparative bio-equivalence of Suanovil 50® and Spiravetox® in healthy broiler chickens after oral administration of both products in a dose of 38 mg spiramycin/kg.b.wt. Twenty four broiler chickens were divided equally into two groups (12 chickens for each group). The first group was designed to study the pharmacokinetics of Suanovil 50®, while the 2nd group was designed to study the pharmacokinetics of Spiravetox®. Each broiler chicken in both groups was orally administered of 38 mg spiramycin/kg.b.wt. Blood samples were obtained from the wing vein and collected immediately before and at 0.08, 0.16, 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours after a single oral administration. The disposition kinetics of Suanovil 50® and Spiravetox® following oral administration of 38 mg spiramycin/kg.b.wt. revealed that the maximum blood concentration [Cmax] were 2.40 and 2.34 μg/ml and attained at [tmax] of 1.69 and 1.83 hours, respectively. In conclusion: Spiravetox® is bioequivalent to Suanovil 50® since the ratios of Cmax, AUC0-24 and AUC0-∞ (T/R) were 0.98, 0.93 and 0.82 respectively. These are within the Bio-equivalence acceptance range. Suanovil 50® and Spiravetox® are therefore bioequivalent and interchangeable.

Keywords: .


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More